Form 4: ALX Oncology Executive Sells Shares for Tax Obligations

ALX Oncology's SVP of Finance and CAO, Shelly Pinto, sold 3,925 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc. (ALXO), reported a transaction.
• On January 6, 2026, Pinto sold 3,925 shares of ALXO common stock.
• The shares were sold at a weighted average price of $1.11 per share, with prices ranging from $1.11 to $1.12.
• The purpose of the sale was to satisfy tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Pinto beneficially owns 88,273 shares of ALXO common stock.
• This total includes 3,000 shares acquired under the company's employee stock purchase plan on December 31, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares to cover tax obligations related to RSU vesting, which is a common occurrence and does not indicate a change in company fundamentals or management's outlook.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, tax-related transaction by an executive and does not signal a change in company fundamentals or strategy.

Key Dates

Recommendation

This Form 4 filing reports a routine sale of shares by an executive to cover tax obligations associated with restricted stock unit vesting. Such transactions are common and typically do not reflect a change in the company's fundamental outlook or the executive's confidence in the company. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

ALX Oncology, ALXO, Form 4, insider trading, stock sale, executive compensation, restricted stock units, tax obligations